Please login to the form below

Not currently logged in
Email:
Password:

obesity

This page shows the latest obesity news and features for those working in and with pharma, biotech and healthcare.

MHRA approves second COVID-19 antibody treatment

MHRA approves second COVID-19 antibody treatment

Risk factors include obesity, older age (> 55 years), diabetes mellitus and heart disease.

Latest news

More from news
Approximately 40 fully matching, plus 342 partially matching documents found.

Latest Intelligence

  • Building the perfect behaviour-change buffet Building the perfect behaviour-change buffet

    Effective policies often use a range of interventions.’. In plain English, to really change the outcome of certain health behaviours – such as obesity levels or eating your five a day – you

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    They include: smoking, excessive alcohol consumption, diabetes, depression, hypertension, hearing impairment and mid-life obesity, in addition to a lack of social contact and physical exercise.

  • The promise of precision medicine The promise of precision medicine

    In Qatar, research into genomics and precision medicine is being used to tackle diseases such as obesity, diabetes and cardiovascular disease. ... This could have an especially positive impact in paediatric obesity, where early intervention can improve

  • Can digital communications boost behaviour change? Can digital communications boost behaviour change?

    the link between obesity and cancer.

  • On our best behaviour On our best behaviour

    Obesity – the ultimate need for behaviour change. Obesity is one of the most visible but relatively neglected public health challenges. ... There is no ‘magic pill’. Anti-obesity medications work best when combined with a lifestyle programme.

More from intelligence
Approximately 2 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Novo Nordisk appoints new senior principal clinical scientist Novo Nordisk appoints new senior principal clinical scientist

    Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    In that position he led a large team of researchers focused on molecular mechanisms that control key functions in the pathogenesis of diabetes and obesity.

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    shareholders became unhappy with the way Vivus handled the launch of its obesity drug Qsymia (phentermine/ topiramat). ... This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity.

  • Burson-Marsteller hires senior DH press officer Burson-Marsteller hires senior DH press officer

    In her previous role, Moore worked with both public health ministers and the chief medical officer, developing proactive and reactive communications strategies for issues including immunisation, genetics, obesity and alcohol.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...